The study of Novartis’s Pluvicto in pre-chemo prostate cancer is a bust on overall survival, with questions raised about trial design.

The presidential session heralds a combo of Padcev and Keytruda as the new front-line bladder cancer standard of care.

But efficacy in NSCLC has slipped since the abstract, and a high rate of rash raises eyebrows.

But efficacy still needs to go up, as several groups try to combine PD-1 and CTLA-4 using differing approaches.

Astra manages to avoid the toxicities that scuppered Lilly’s PD-1 x TIM-3 contender, but still needs to dial up sabestomig’s efficacy.

But toxicity will be closely watched in future trials.